Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes

Journal of Clinical Neuroscience

Volumn 16, Issue 2, 2009, Pages 246-252

  Bairactaris, C ^a   Demakopoulos, N ^a   Tripsianis, G ^b   Sioka, C ^b   Farmakiotis, D ^a   Vadikolias, K ^b   Heliopoulos, I ^b   Georgoulias, P ^c   Tsougos, I ^c   Papanastasiou, I ^a   Piperidou, C ^b  

^a NIMTS HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

123I ioflupane; Dopamine transporter; Parkinsonism; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; IOFLUPANE I 123; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CONFIDENCE INTERVALS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NORTROPANES; PARKINSONIAN DISORDERS; PROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 58149310895     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.01.020     Document Type: Article

References (34)

1. Albanese A. Diagnostic criteria for Parkinson's disease. Neurol Sci 24 (2003) S236
2. Cohen O., Pullman S., Jurewicz E., et al. Rest tremor in patients with essential tremor, prevalence, clinical correlates and electrophysiology characteristics. Arch Neurol 60 (2003) 405-410
3. Oertel W., Gerstner A., Hoffken H., et al. Role of dopamine transporter SPECT for the practitioner and the general neurologist. Mov Disord 18 Suppl.7 (2003) 9-15
4. Hughes A., Daniel S., and Lees A. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (2001) 1497-1499
5. Catafau A.M., and Tolosa E. The DaTSCAN clinically uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using [123I] Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian Syndromes. Mov Disord 19 (2004) 1175-1182
6. Rajput A.H., Rozdilsky B., and Rapjput A. Accuracy of clinical diagnosis in parkinsonism: A prospective study. Can J Neurol Sci 18 (1991) 275-278
7. Hughes A.J., Daniel S.E., Ben-Shlomo Y., et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
8. Gibb W.R., and Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988) 745-752
9. Marshall V., and Grosset D.G. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 18 Suppl.7 (2003) 22-27
10. Benamer H.T., Oertel W.H., Patterson J., et al. Prospective study of presynaptic dopaminergic imaging in patients with mild Parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 18 (2003) 977-984
11. Poewe W., and Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 18 Suppl.7 (2003) 16-21
12. Chaudhuri K.R., Buxton-Thomas M., Dhawan V., et al. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: Clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry 76 (2005) 115-117
13. Schwartz M., Groshar D., Inzelberg R., et al. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. Parkinsonism Relat Disord 10 (2004) 385-389
14. Booij J., Hemelaar T.G., Speelman J.D., et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I] FPCIT SPECT. J Nucl Med 40 (1999) 753-761
15. Benamer T.S., Patterson J., Grosset D.G., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 15 (2000) 503-510
16. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47 (1996) 1-9
17. Wenning G.K., Seppi K., Scherfler C., et al. Multiple system atrophy. Sem Neurol 21 (2001) 33-40
18. Elble R.J. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 54 11 Suppl.4 (2000) 2-6
19. Tatsch K., Asenbaum S., Bartenstein P., et al. European Association of Nuclear Medicine Procedure Guidelines for brain neurotransmission SPET using [123I]-labelled dopamine (D2) transporter ligands. Eur J Nucl Med 29 (2002) BP30-BP35
20. Laruelle M., Wallace M., Seibyl J.P., et al. Graphical, kinetic and equilibrium analyses of in vivo [123I] β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14 (1994) 982-994
21. Seibyl J.P., Marek K.L., Quinlan D., et al. Decreased single-photon emission computed tomographic [123I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 (1995) 589-598
22. Koch W., Hornung J., Hamann C., et al. Equipment-independent reference values for dopamine transporter imaging with [123I]-FP-CIT. Nuklearmedizin 46 (2007) 107-111
23. Feinstein A.R., and Cicchetti D.V. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol 43 (1990) 543-549
24. Cicchetti D.V., and Feinstein A.R. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol 43 (1990) 551-558
25. Schrag A., Ben-Shlomo Y., and Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community?. J Neurol Neurosurg Psychiatry 73 (2002) 529-534
26. Jennings D.L., Seibyl J.P., Oakes D., et al. (123I) β-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome. Arch Neurol 61 (2004) 1224-1229
27. Dodel R.C., Hoffken H., Moller J.C., et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision analytic approach. Mov Disord 18 Suppl.7 (2003) 52-62
28. Marshall V., and Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18 (2003) 1415-1423
29. Covelli E.M., Brunetti A., Di Lauro A., et al. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease. Radiol Med 108 (2004) 417-425
30. Eerola J., Tienari P.J., Kaakkola S., et al. How useful is [123I] β-CIT SPECT in clinical practice?. J Neurol Neurosurg Psychiatry 76 (2005) 1211-1216
31. Marshall V.L., Patterson J., Hadley D.M., et al. Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Mov Disord 21 (2006) 2247-2250
32. Antonini A., Benti R., De Notaris R., et al. [123I]-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24 (2003) 149-150
33. Booij J., Speelman J.D., Horstink M.W., et al. The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic Parkinsonism from those with other forms of Parkinsonism. Eur J Nucl Med 28 (2001) 266-272
34. Scherfler C., Schwarz J., Antonini A., et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22 (2007) 1229-1238